Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place from September 4-6, 2024, at the Marriott Marquis in New York City.

Key executives, including CEO Ben Zeskind and CSO Brett Hall, will present in a fireside chat format on September 6 from 10:00 – 10:35 am ET. They will discuss Immuneering's pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for broad populations of cancer patients.

The presentation will be webcast live and archived on Immuneering's website in the Investor Relations section. This event provides an opportunity for investors to gain insights into the company's progress and future plans in the oncology field.

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Morgan Stanley 22^nd Annual Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from September 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer and Secretary and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

Format: Fireside Chat and 1x1 Investor Meetings

Date/Time: September 6 from 10:00 – 10:35 am ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

FAQ

When is Immuneering (IMRX) presenting at the Morgan Stanley Healthcare Conference?

Immuneering (IMRX) is presenting on September 6, 2024, from 10:00 – 10:35 am ET at the Morgan Stanley 22nd Annual Global Healthcare Conference.

Where can I watch Immuneering's (IMRX) presentation at the Morgan Stanley conference?

The presentation will be webcast live and archived in the Investor Relations section of Immuneering's website under Events & Presentations.

What will Immuneering (IMRX) discuss at the Morgan Stanley Healthcare Conference?

Immuneering (IMRX) will discuss their pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for cancer patients.

Which Immuneering (IMRX) executives are participating in the Morgan Stanley conference?

Participating executives include Ben Zeskind (CEO), Brett Hall (CSO), Harold Brakewood (CBO), Michael Bookman (CLO), and Mallory Morales (CAO and Treasurer).